Filana Therapeutics, Inc.
NCM: FLNALive Quote
📈 ZcoreAI Score
Our AI model analyzes Filana Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get FLNA Z-Score →About Filana Therapeutics, Inc.
Healthcare
Biotechnology
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.
📊 Fundamental Analysis
Filana Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -82.7%, which indicates that capital utilization is currently under pressure.
At a current price of $1.64, FLNA currently trades near the bottom of its 52-week range (10%), indicating potential value or weakness (Range: $1.28 - $4.98).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$79.22M
Trailing P/E
--
Forward P/E
--
Beta (5Y)
-0.68
52W High
$4.98
52W Low
$1.28
Avg Volume
640K
Day High
Day Low